Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?

Bio-Techne (TECH) reported Q4 adjusted EPS of 52 cents, meeting consensus estimates but declining 1.9% year-over-year. Full-year adjusted EPS of $1.93 increased 0.5% and surpassed consensus by 1%. Q4 revenues of $321.2 million exceeded estimates by 1.26%, though organic growth was modest at 3%. The company improved its balance sheet with cash increasing to $264.7 million and debt declining to $200 million. However, analysts have issued no estimate revisions in the past two months, and the stock carries a Zacks Rank #3 (Hold) with weak growth and momentum scores.